Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancer
New Podcast
Skip to content
FOR INVESTORS
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Onvansertib
Pipeline
Clinical Programs
mCRC
mCRPC
mPDAC
Leadership
Management Team
Board of Directors
Scientific Advisory Board
Contact Us
For Investors
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Investor Relations
Press Releases
Events
Events
Get News Alerts by Email
2022
2023
January
February
March
April
May
June
July
August
September
October
November
December
All Categories
Financial Conferences
Webcasts
GO
Upcoming Events
Past Events
No events to display
Loading Events...
Load More Events
